Markets

Kailera Therapeutics Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program; Topline Data Now Expected In Mid-2028

Sep 30, 2026 · 07:04 AM ET· updated 1h ago

- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher- Topline data now expected in mid-2028WALTHAM, Mass., Sept. 30, 2026

Why It Matters

Kailera finished signing up patients for a big weight loss medicine test. Results won't come until mid-2028, so there is a long wait ahead.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

KLRA11.28

+0.29 (+2.59%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.